(News Bulletin 247) – Pfizer announced on Friday that the United States Food and Drug Administration (FDA) has approved its application for an extension of indication for CIBINQO® (abrocitinib) to include adolescents aged 12 to 18 with refractory, moderate to severe atopic dermatitis (AD), whose disease is not sufficiently controlled by other systemic medicinal products or when the use of these treatments is not recommended.
Until then, CIBINQO was only approved for the treatment of people over 18 years of age.
‘This is a significant step forward for many teenagers across the United States. who are affected by the persistent itching and discomfort that accompanies moderate to severe uncontrolled atopic dermatitis,” said Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital in San Diego.
“CIBINQO’s extension of indication offers potential relief to young patients with atopic dermatitis in need and their families,” he added.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
